Based in India, Ankit is a financial content writer and stock market
analyst. He has worked for almost a decade on several financial
projects related to the stock market news, fundamental research and
technical analysis for several websites. He obtained his Masters
Degree In finance (MS – finance) from ICFAI. Currently, he serves as
a financial consultant and technical analyst at Tradersinsights.com.
PHAS stock has been on fire over the past month, gaining over 440% during this period. Today PhaseBio Pharmaceuticals (NASDAQ:PHAS) is valued at more than $350 million. This week, PHAS stock leaped 32.5% after the …
DERM stock investors are getting excited and for good reason too. Dermira (NASDAQ:DERM) released positive progress for a key drug candidate, lebrikizumab, back in mid-March and shares have been climbing since.
All seems well right now for CHK stock, which, last year, plunged dangerously. To be sure, Chesapeake Energy Corporation (NYSE:CHK) shares lost 47% of their value when the price of crude oil tanked. However, CHK …
ZYNE stock continued to gain momentum in Friday’s session and was recently moving up by 10.36% to $8.53 USD, extending its winning streak for the fourth straight session. Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are up …
We’ve shortlisted four major biotech stocks with upcoming news in April related to FDA decisions. Where will the news take GW Pharmaceuticals (NASDAQ:GWPH), FibroGen (NASDAQ:FGEN), Heron Therapeutics (NASDAQ:HRTX), and Assembly Biosciences (NASDAQ:ASMB)?